Table 1 Cytotoxic activities of complexes 1–5 and their IC50 values (μM)a.

From: Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Complexes

1

2

3

4

cisplatin

HeLa

>100

55.4 ± 3.1

22.5 ± 3.3

2.4 ± 0.3

15.1 ± 2.1

A549

>100

43.4 ± 5.3

28.6 ± 2.6

1.0 ± 0.2

21.3 ± 3.3

A549R

>100

48.2 ± 2.7

32.2 ± 1.5

0.8 ± 0.1

142.5 ± 5.4

LO2

>100

75.8 ± 7.5

45.6 ± 3.8

6.7 ± 2.4

18.9 ± 2.6

MCTSsb

>100

95.7

60.6 ± 5.5

1.8 ± 0.3

>200

Resistant Indexc

–

1.11

1.13

0.8

6.69

  1. aCells were treated with various concentrations of the complexes for 48 h.
  2. bA549R MCTSs (~400 μM in diameter) were treated with various concentrations of the complexes for 48 h.
  3. cIC50(A549R)/IC50(A549). Each value represents the mean ± SD of three independent experiments.
Back to article page